Pulmonary Embolism Response Team utilization during the COVID-19 pandemic

Autor: Martin B. Leon, Philip Green, Amir Masoumi, Shayan Nabavi Nouri, Shawn Gogia, Erika B. Rosenzweig, Mahesh V. Madhavan, Anthony Pucillo, Justin Fried, Matthew Finn, Cara I Agerstrand, Matthew Cohen, Sahil A. Parikh, Andrew J. Einstein, Nir Uriel, Andrew Eisenberger, Ajay J. Kirtane, Joseph Ingrassia, Koji Takeda, Daniel Brodie, Sanjum S. Sethi, Yevgeniy Brailovsky
Rok vydání: 2021
Předmět:
Adult
Male
medicine.medical_specialty
Time Factors
Coronavirus disease 2019 (COVID-19)
venous thromboembolism
Hemorrhage
030204 cardiovascular system & hematology
Risk Assessment
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
Pandemic
medicine
Clinical endpoint
Humans
Thrombolytic Therapy
In patient
Hospital Mortality
030212 general & internal medicine
Practice Patterns
Physicians'
pulmonary embolism response team (PERT)
Aged
Retrospective Studies
Aged
80 and over
Patient Care Team
Health Services Needs and Demand
Inpatient mortality
SARS-CoV-2
business.industry
COVID-19
Anticoagulants
Middle Aged
medicine.disease
Pulmonary embolism
Treatment Outcome
Health Resources
Female
Original Article
Fibrinolytic therapy
Pulmonary Embolism
Cardiology and Cardiovascular Medicine
business
Venous thromboembolism
Zdroj: Vascular Medicine (London, England)
ISSN: 1477-0377
1358-863X
Popis: Coronavirus disease 2019 (COVID-19) may predispose patients to venous thromboembolism (VTE). Limited data are available on the utilization of the Pulmonary Embolism Response Team (PERT) in the setting of the COVID-19 global pandemic. We performed a single-center study to evaluate treatment, mortality, and bleeding outcomes in patients who received PERT consultations in March and April 2020, compared to historical controls from the same period in 2019. Clinical data were abstracted from the electronic medical record. The primary study endpoints were inpatient mortality and GUSTO moderate-to-severe bleeding. The frequency of PERT utilization was nearly threefold higher during March and April 2020 ( n = 74) compared to the same period in 2019 ( n = 26). During the COVID-19 pandemic, there was significantly less PERT-guided invasive treatment (5.5% vs 23.1%, p = 0.02) with a numerical but not statistically significant trend toward an increase in the use of systemic fibrinolytic therapy (13.5% vs 3.9%, p = 0.3). There were nonsignificant trends toward higher in-hospital mortality or moderate-to-severe bleeding in patients receiving PERT consultations during the COVID-19 period compared to historical controls (mortality 14.9% vs 3.9%, p = 0.18 and moderate-to-severe bleeding 35.1% vs 19.2%, p = 0.13). In conclusion, PERT utilization was nearly threefold higher during the COVID-19 pandemic than during the historical control period. Among patients evaluated by PERT, in-hospital mortality or moderate-to-severe bleeding were not significantly different, despite being numerically higher, while invasive therapy was utilized less frequently during the COVID-19 pandemic.
Databáze: OpenAIRE
Externí odkaz: